Skip to main content

Bispecific Antibody Deal Benchmarks in Oncology

Median Upfront
$348M
Range: $194M - $492M
Total Deal Value
$2.2B
Range: $1.4B - $3.0B
Royalty Rate
12.9% - 21.1%
Tiered up to 25.1%
Dev Milestones
$466M
Range: $311M - $623M
Model Your Deal

Market Analysis

Bispecific Antibody therapies in oncology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 bispecific antibody asset in oncology is $348M, with total deal values reaching $2.2B. Development milestones average $466M, while regulatory milestones contribute $745M.

The oncology bispecific antibody landscape is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for bispecific antibody oncology deals range from 12.9% to 21.1% at the base tier, with tiered escalation reaching 16.9%-25.1% on blockbuster sales. Commercial milestones averaging $652M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a bispecific antibody oncology licensing deal?
Based on our analysis, Phase 2 bispecific antibody licensing deals in oncology average $348M in upfront payments, with a range of $194M to $492M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for bispecific antibody oncology transactions?
The median total deal value for Phase 2 bispecific antibody assets in oncology is $2.2B, ranging from $1.4B to $3.0B. This includes development milestones ($466M), regulatory milestones ($745M), and commercial milestones ($652M).
What royalty rates are standard for bispecific antibody deals in oncology?
Base royalty rates for bispecific antibody oncology transactions range from 12.9% to 21.1%, with tiered escalations reaching 16.9%-25.1% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in bispecific antibody oncology deals?
Bispecific Antibody oncology deals allocate approximately 84% of total deal value to milestones. Development milestones ($466M) make up the largest share, followed by commercial milestones ($652M) and regulatory milestones ($745M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Oncology

View

Monoclonal Antibody in Oncology

View

Bispecific Antibody in Neurology

View

Bispecific Antibody in Immunology & Autoimmune

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included